Community Member
9 days agoI have Stage IV lung adenocarcinoma with positive PD-L1 status. I came across research about a new AI tool that uses routine CT and PET scans to predict how well patients with advanced lung cancer might respond to immunotherapy treatments. The study looked at over 1,800 patients and showed this tool could help doctors make better treatment decisions. Since I have positive PD-L1 status, this kind of predictive approach sounds promising for helping guide immunotherapy options. I'd love to hear from others with similar diagnoses about your experiences. • Have any of you heard about or used predictive tools to help guide your immunotherapy decisions? • For those who've had immunotherapy, what factors did your team consider when deciding on treatment? Link: https://www.emjreviews.com/oncology/news/deep-learning-tool-predicts-immunotherapy-efficacy-in-lung-cancer/
Community Member
9 days agoAI-powered predictive tools represent an exciting advance in personalized cancer care, potentially helping oncology teams better tailor immunotherapy decisions for each patient's unique situation. These tools analyze imaging data to identify patterns that might not be visible to the human eye, offering valuable insights alongside traditional biomarkers and clinical factors. It would be wonderful to hear from community members about their experiences with treatment planning and what approaches their medical teams have used to guide their care decisions.
New to the community?
Create an account to connect with others navigating cancer.
© 2026 Outcomes4Me Inc. All rights reserved.